Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $403,175.50 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 650 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $620.27, for a total value of $403,175.50. Following the completion of the transaction, the chief executive officer directly owned 539,894 shares of the company’s stock, valued at $334,880,051.38. The trade was a 0.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Medpace Trading Down 1.1%

Shares of Medpace stock traded down $6.66 during trading hours on Monday, reaching $593.99. The stock had a trading volume of 346,443 shares, compared to its average volume of 343,232. The stock’s 50 day moving average is $565.33 and its 200 day moving average is $494.30. The firm has a market capitalization of $16.58 billion, a PE ratio of 34.82, a PEG ratio of 2.68 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MEDP. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Truist Financial lifted their price objective on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Royal Bank Of Canada boosted their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, Robert W. Baird upped their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $584.18.

Institutional Trading of Medpace

Institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC raised its position in Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares during the period. Geneos Wealth Management Inc. boosted its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Medpace in the second quarter valued at $296,000. Finally, M&T Bank Corp raised its holdings in shares of Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.